PT2344198T - Preparações farmacêuticas à base de lípidos para aplicação tópica - Google Patents

Preparações farmacêuticas à base de lípidos para aplicação tópica

Info

Publication number
PT2344198T
PT2344198T PT98169402T PT09816940T PT2344198T PT 2344198 T PT2344198 T PT 2344198T PT 98169402 T PT98169402 T PT 98169402T PT 09816940 T PT09816940 T PT 09816940T PT 2344198 T PT2344198 T PT 2344198T
Authority
PT
Portugal
Prior art keywords
oral
compositions
methods
topical application
pharmaceutical preparations
Prior art date
Application number
PT98169402T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2344198(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of PT2344198T publication Critical patent/PT2344198T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PT98169402T 2008-09-27 2009-09-25 Preparações farmacêuticas à base de lípidos para aplicação tópica PT2344198T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27

Publications (1)

Publication Number Publication Date
PT2344198T true PT2344198T (pt) 2020-12-04

Family

ID=42060413

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98169402T PT2344198T (pt) 2008-09-27 2009-09-25 Preparações farmacêuticas à base de lípidos para aplicação tópica

Country Status (15)

Country Link
US (1) US9750812B2 (enExample)
EP (1) EP2344198B1 (enExample)
JP (3) JP2012504135A (enExample)
CA (1) CA2737025C (enExample)
CY (1) CY1123579T1 (enExample)
DK (1) DK2344198T3 (enExample)
ES (1) ES2834006T3 (enExample)
HR (1) HRP20201860T1 (enExample)
HU (1) HUE052571T2 (enExample)
LT (1) LT2344198T (enExample)
MX (1) MX2011003207A (enExample)
PL (1) PL2344198T3 (enExample)
PT (1) PT2344198T (enExample)
SI (1) SI2344198T1 (enExample)
WO (1) WO2010036947A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590950A (en) 2008-07-18 2012-12-21 Biomod Concepts Inc Articles of manufacture releasing an active ingredient
US8691518B2 (en) 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
WO2012148174A2 (ko) * 2011-04-25 2012-11-01 Park Jun-Hyoung 탈모방지 및 발모촉진용 외용제 조성물
US20150182542A1 (en) * 2012-02-16 2015-07-02 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022034B1 (pt) * 2012-08-31 2020-02-18 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida, suspensão aquosa contendo a mesma, composição para tratamento de alopecia, processo de preparação de dita composição, e seu uso
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
US20150313829A1 (en) * 2012-11-26 2015-11-05 Roberto Queiroga Lautner Topical formulations for the prevention and treatment of alopecia and inhibition of hair growth
JP6595454B2 (ja) * 2013-05-03 2019-10-23 リピドール エービー 薬学的又は化粧学的活性成分を投与するための局部用組成物及びキャリアー
KR102647719B1 (ko) 2013-08-15 2024-03-14 마리 케이 인코포레이티드 주름 치료를 위한 국소 피부 조성물
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
ES2831319T3 (es) * 2013-11-17 2021-06-08 Medrx Co Ltd Formulación líquida coloidal absorbente transdérmica
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
ES2952159T3 (es) 2014-10-29 2023-10-27 Samson Clinical Pty Ltd Minoxidil oral para el tratamiento de alopecia areata
EP3038053B1 (en) 2014-12-22 2019-11-06 Reactive Reality GmbH Method and system for generating garment model data
CN107530235B (zh) * 2015-04-13 2021-09-17 方丹科技国际股份有限公司 用于生产超小型脂质结构的一步法
JPWO2016186157A1 (ja) * 2015-05-19 2018-03-08 株式会社 メドレックス 経皮吸収型液剤
ES2991863T3 (es) * 2016-04-19 2024-12-05 Univ Nanyang Tech Nanoliposomas para la administración sostenida de tacrolimus para el tratamiento de enfermedades oculares del segmento anterior
CU20190046A7 (es) 2016-10-28 2019-12-03 Servier Lab Composición de concentrado orgánico que comprende ácido 2-{[5-{ 3-cloro-2-metil-4-[2-( 4-metilpiperazin-1-il)etoxi]fenil} -6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oxi}-3-(2-{ [2-(2-metoxifenil)pirimidin-4-il]metoxi} fenil)propanoico y, composiciones liposomales que la contienen
JP7291633B2 (ja) * 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アジュバントを製造する方法
KR102663164B1 (ko) * 2017-07-12 2024-05-07 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
CA3080205A1 (en) * 2017-10-27 2019-05-02 TopiRX Therapeutics Inc. Topical formulations for treating dermatological disorders including male pattern baldness
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
JP2022506944A (ja) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2021232054A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
AU2024251515A1 (en) * 2023-04-14 2025-12-04 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticles targeting spleen
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585967D1 (de) * 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
DE3576117D1 (de) 1984-09-24 1990-04-05 Michael Mezei Mehrphasige pharmazeutische zusammensetzung.
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
EP0285382B1 (en) 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
WO1989005636A1 (en) 1987-12-22 1989-06-29 The Liposome Company, Inc. Spontaneous vesiculation of multilamellar liposomes
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
WO1990011780A1 (en) 1989-03-31 1990-10-18 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
JPH0971513A (ja) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JP3596835B2 (ja) * 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6265412B1 (en) 1998-05-26 2001-07-24 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
WO2000053177A1 (en) * 1999-03-11 2000-09-14 Fujisawa Pharmaceutical Co., Ltd. Liposome preparations
CA2309373A1 (en) 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
JP4780429B2 (ja) 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
AU2001259484A1 (en) * 2000-05-05 2001-11-20 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
IN188843B (enExample) * 2000-06-22 2002-11-09 Vinod Daftary Gautam Dr
EP1313479A4 (en) 2000-07-19 2005-09-21 W Roy Knowles PREVENTION OF HAIR LOSS
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
PT1389089E (pt) * 2001-03-27 2009-11-30 Phares Pharm Res Nv Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
JP4796260B2 (ja) 2001-04-05 2011-10-19 大正製薬株式会社 ミノキシジル含有製剤
US7045550B2 (en) * 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
CA2495913A1 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
JP5170940B2 (ja) * 2002-10-03 2013-03-27 ユニバースィティ オブ ミシシッピー 高純度アンホテリシンｂを含有する組成物
EA200500659A1 (ru) * 2002-10-16 2005-10-27 Неофарм, Инк. Способ получения кардиолипина или его аналога (варианты) и содержащей их липосомы, способы использования кардиолипина или его аналогов в лечении болезней (варианты) и содержащая их композиция (варианты) и ее применение
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
EP1802742A2 (en) * 2004-08-30 2007-07-04 IKEN Tissue Therapeutics, Inc. Compositions and methods of promoting hair growth
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
WO2008127358A2 (en) 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN101559038B (zh) 2009-05-21 2011-03-16 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Also Published As

Publication number Publication date
EP2344198A4 (en) 2013-01-09
PL2344198T3 (pl) 2021-05-31
EP2344198B1 (en) 2020-11-04
ES2834006T3 (es) 2021-06-16
LT2344198T (lt) 2021-02-25
CA2737025A1 (en) 2010-04-01
US9750812B2 (en) 2017-09-05
WO2010036947A3 (en) 2010-06-10
JP2014221784A (ja) 2014-11-27
WO2010036947A2 (en) 2010-04-01
MX2011003207A (es) 2011-11-04
HUE052571T2 (hu) 2021-05-28
SI2344198T1 (sl) 2021-01-29
EP2344198A2 (en) 2011-07-20
JP2012504135A (ja) 2012-02-16
JP2017048188A (ja) 2017-03-09
JP6196943B2 (ja) 2017-09-13
US20110212167A1 (en) 2011-09-01
CA2737025C (en) 2012-09-04
HRP20201860T1 (hr) 2021-04-16
CY1123579T1 (el) 2022-03-24
DK2344198T3 (da) 2020-11-30

Similar Documents

Publication Publication Date Title
PT2344198T (pt) Preparações farmacêuticas à base de lípidos para aplicação tópica
IL275854A (en) Pharmaceutical composition and its administration
TWI367110B (en) Topical pharmaceutical formulation
EP2331072B8 (en) Methods and compositions for oral administration of proteins
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
IL204589A0 (en) Cosmetic or pharmaceutical composition for topical application
PL2224973T3 (pl) Środki konserwujące do kosmetyków, środków do pielęgnacji ciała i kompozycji farmaceutycznych
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
EP2199402A4 (en) CYCLOASTRAGENOL MONOGLYCOSIDE, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
PL2344130T3 (pl) Kompozycje farmaceutyczne do miejscowego stosowania
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
IL213588A0 (en) Naphthyridine derivatives, their preparation and pharmaceutical compositions containing them
IL206936A0 (en) 2-amino-2-phenylalkanol derivatives, preparation thereof and pharmaceutical compositions containing same
EP2565180A4 (en) ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH
ZA201102405B (en) Pharmaceutical composition for oral administration
ZA201200165B (en) 2-amino-2phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same
GB0612556D0 (en) Topical pharmaceutical formulations